Please login to the form below

Not currently logged in
Email:
Password:

Czech biotech Sotio selects Chiltern International

UK CRO will work on late-stage trials for its prostate cancer therapy

UK headquartered contract research organisation (CRO) Chiltern International has been appointed by Czech biotech Sotio to carry out phase III clinical trials.

Under the agreement, the CRO will provide full-service management of the phase III trials, entitled Viable, which will involve 126 treatments for 750 prostate cancer patients from across Europe.

The trials will assist the biotech company's development of Active Cellular Immunotherapy (ACI), which focuses on cancer and autoimmune disease treatments - specifically, therapies using an immunotherapy platform based activated dendritic cells.

Chiltern will also be responsible for processing the data obtained during the clinical evaluation.

"I am very pleased that we have been selected to manage this high profile trial," said Chiltern CEO Dr Jim Esinhart.

"I believe it underscores the strengths and expertise of our global oncology therapeutic area team. We look forward to working in close partnership with Sotio deliver a quality outcome."

Viable will be a global clinical trial, tracking a total of 1,170 prostate cancer patients from Europe and the US.

19th March 2013

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Complete Medical Communications (CMC)

CMC is a leading global agency dedicated to healthcare communications across the lifecycle. We combine scientific acumen, excellence in delivery...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics